Abiraterone Acetate

Evidence Level: L5

Predicted Indications: 0

---

Table of Contents

1. Abiraterone Acetate
2. Abiraterone Acetate: Evidence Pack Incomplete — Unable to Generate Repurposing Prediction Report
   1. One-Sentence Summary
   2. Quick Overview
   3. Taiwan Market Information
   4. Safety Considerations
   5. Conclusion and Next Steps
   6. Disclaimer

---

## Pharmacist Assessment Report

Abiraterone Acetate: Evidence Pack Incomplete — Unable to Generate Repurposing Prediction Report

One-Sentence Summary

Abiraterone acetate is an androgen biosynthesis inhibitor used for prostate cancer treatment, approved and marketed in multiple countries. However, this Evidence Pack lacks records of original indications, TxGNN prediction results, and safety data, and a complete drug repurposing assessment cannot currently be performed. Taiwan’s drug database also shows that this drug has not yet been marketed in Taiwan (0 licenses).

---

Quick Overview

Item	Content
Original indication	No data in this Evidence Pack
Predicted new indications	None (TxGNN prediction result is empty)
TxGNN prediction score	N/A
Evidence level	N/A
Taiwan market status	✗ Not marketed
Number of licenses	0
Recommended decision	Hold

---

Taiwan Market Information

This Evidence Pack has no records of any market approval in Taiwan’s drug database (total_licenses = 0).

Note: DrugBank query (query_log ID 2) returned successfully (result_count = 1), but the drugbank_id field is null, indicating that data has not been correctly integrated into this Evidence Pack. It is recommended to re-execute the DrugBank mapping process to obtain complete drug information.

---

Safety Considerations

Please refer to the SmPC for safety information.

---

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack has data gaps in three critical dimensions: TxGNN prediction results are empty, original indications and MOA have not been obtained, and all safety data is missing, making it unable to support any repurposing assessment conclusion.

To proceed, the following is needed:

• [Blocking] Complete drugbank_id, MOA, and original indications from DrugBank; the DrugBank query has returned 1 result, which needs to be parsed and written to the Evidence Pack
• [Blocking] Execute the TxGNN prediction process to obtain the predicted_indications list; the prediction array is currently empty, making any repurposing analysis impossible
• [Blocking] Download and parse Taiwan TFDA package insert PDF to obtain warnings, contraindications, and drug interaction data
• [High] Confirm Taiwan market status; abiraterone acetate has market records in international markets such as FDA/EMA, and the Taiwan Not marketed status requires further verification
• After completing the above data supplementation, regenerate Evidence Pack v5 and initiate the formal assessment process

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---